ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 559,87
-0,65%
Dow Jones
39 127,80
0,04%
DAX
18 171,69
0,04%
Brent Oil
84,775
0,36%
Bitcoin
61 124,09
0,51%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Tempest Therpeutics Inc (TPST)

  7. Tempest Therpeutics Inc (TPST) Actualités

TPST

Tempest Therpeutics (TPST)

Tempest Therpeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TPST
DateHeureSourceTitreSymboleSociété
20/06/202414h32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TPSTTempest Therpeutics Inc
20/06/202414h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TPSTTempest Therpeutics Inc
20/06/202414h00GlobeNewswire Inc.Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control ArmNASDAQ:TPSTTempest Therpeutics Inc
19/06/202400h22GlobeNewswire Inc.Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular CarcinomaNASDAQ:TPSTTempest Therpeutics Inc
15/06/202400h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TPSTTempest Therpeutics Inc
07/06/202410h30GlobeNewswire Inc.Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TPSTTempest Therpeutics Inc
21/05/202414h00GlobeNewswire Inc.Tempest to Participate in Upcoming Investor ConferencesNASDAQ:TPSTTempest Therpeutics Inc
13/05/202422h54Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TPSTTempest Therpeutics Inc
09/05/202422h29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TPSTTempest Therpeutics Inc
09/05/202422h29GlobeNewswire Inc.Tempest Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TPSTTempest Therpeutics Inc
09/04/202414h00GlobeNewswire Inc.Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingNASDAQ:TPSTTempest Therpeutics Inc
04/04/202414h00GlobeNewswire Inc.Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsNASDAQ:TPSTTempest Therpeutics Inc
19/03/202421h25GlobeNewswire Inc.Tempest Reports Year End 2023 Financial Results and Provides Business UpdateNASDAQ:TPSTTempest Therpeutics Inc
12/03/202413h00GlobeNewswire Inc.Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer TypesNASDAQ:TPSTTempest Therpeutics Inc
05/03/202422h30GlobeNewswire Inc.Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual MeetingNASDAQ:TPSTTempest Therpeutics Inc
26/02/202414h00GlobeNewswire Inc.Tempest to Present at the 44th Annual TD Cowen Healthcare ConferenceNASDAQ:TPSTTempest Therpeutics Inc
15/02/202400h49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TPSTTempest Therpeutics Inc
20/11/202314h00GlobeNewswire Inc.Tempest to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:TPSTTempest Therpeutics Inc
17/11/202322h46Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:TPSTTempest Therpeutics Inc
17/11/202322h39Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TPSTTempest Therpeutics Inc
08/11/202323h17GlobeNewswire Inc.Tempest Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TPSTTempest Therpeutics Inc
02/11/202321h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TPSTTempest Therpeutics Inc
11/10/202314h29Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:TPSTTempest Therpeutics Inc
11/10/202314h01GlobeNewswire Inc.Tempest Adopts Limited Duration Stockholder Rights PlanNASDAQ:TPSTTempest Therpeutics Inc
11/10/202314h00GlobeNewswire Inc.Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC StudyNASDAQ:TPSTTempest Therpeutics Inc
10/10/202322h05GlobeNewswire Inc.Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular CarcinomaNASDAQ:TPSTTempest Therpeutics Inc
19/09/202314h00GlobeNewswire Inc.Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and DevelopmentNASDAQ:TPSTTempest Therpeutics Inc
05/09/202314h00GlobeNewswire Inc.Tempest to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TPSTTempest Therpeutics Inc
10/08/202322h13GlobeNewswire Inc.Tempest Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TPSTTempest Therpeutics Inc
19/07/202314h00GlobeNewswire Inc.Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 TogetherNASDAQ:TPSTTempest Therpeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TPST

Dernières Valeurs Consultées

EU
BLEE
Bleecker
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés